To investigate the clinical pathological features and prognosis of high expression CXCL12 and IGF1 gastric cancer, and to provide evidence for the diagnosis and treatment of gastric cancer.

The clinical data of 81 patients with gastric cancer from March 2014 to March 2017 in our hospiatal were retrospectively analyzed. The expression of CXCL12 and IGF1 in cancer tissue, adjacent tissues (1cm away from cancer tissue) and normal tissues were detected by Immunohistochemistry (IHC) method. The data was analyzed by using SPSS20.0 software. The expression levels of CXCL12 and IGF1 in different gastric tissues were expressed as %, and was compared by using χ² test; The survival curves were plotted by using Kaplan-Meier method, and the survival curves were compared using the Log-rank method. A P value <0.05 was considered as statistically significant difference.

The expression levels of CXCL12(53.1%) and IGF1(49.4%) in gastric cancer tissue were significantly higher than (40.7%, 39.5%) in adjacent tissues and (7.4%, 8.6%) in normal tissues (P<0.05). The survival time of patients with high expression CXCL12 (median survival time of 13 months) and IGF1 (median survival time of 17 months) in gastric cancer was significantly lower than those of low expression patients (median survival time of 64 and 65 months, respectively) with significant difference (P<0.05).

The expression of CXCL12 and IGF1 in gastric carcinoma were significantly higher than those in normal and paraconticous tissues, it could serve as a basis for the diagnosis of stomach cancer. High expression CXCL12 and IGF1 gastric cancer patients has higher malignancy, more easily metastases, and poor prognosis.